J&J loses latest talc case; ordered to pay $40M to two women
A California jury on Friday found in favor of two women who sued Johnson & Johnson (JNJ), alleging that the healthcare...
Tag: JNJ
J&J’s Akeega granted expanded indication in prostate cancer
The U.S. FDA has expanded the indication for Johnson & Johnson's (JNJ) Akeega (niraparib and abiraterone) to include...
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma
Biogen (BIIB) traded lower on Wednesday after HSBC downgraded the company from Hold to Reduce, handing the Alzheimer’s...
Ligand Pharma sets 2026 outlook as Citi starts at Buy on valuation
As J&J (JNJ) partner Ligand Pharma (LGND) held its Investor Day in New York City on Tuesday, Citi initiated its coverage...
JNJ releases new data bolstering Inlexzo for bladder cancer
A phase 2 study of Johnson & Johnson's Inlexzo (gemcitabine intravesical system) found strong survival results after...
Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma
Arcellx (ACLX) closed down ~17% Monday after privately held Kelonia Therapeutics released early-stage results from a small...
Key deals this week: Kenvue, Warner Bros. Discovery, Adobe, Workday and more
Here's a list of key deals reported across sectors this week: Kenvue (KVUE) rose 3% amid some speculation about a possible...
J&J, Halozyme win FDA traditional nod for Darzalex Faspro in AL amyloidosis
The U.S. FDA on Thursday granted traditional approval for Darzalex Faspro, an injectable version of the multiple myeloma...
Johnson & Johnson falls after six-sessions of gain
Johnson & Johnson (JNJ) slipped 0.18% to $199.22 in afternoon trade on Tuesday, ending six-sessions of gain. Despite...
Zymeworks shifts to a royalty-driven business model
Zymeworks (ZYME) on Tuesday announced plans to focus on a royalty-driven growth model backed by its internal R&D engine...